Rezolute Inc (RZLT) - Total Liabilities
Based on the latest financial reports, Rezolute Inc (RZLT) has total liabilities worth $8.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Rezolute Inc to see how much of total assets are deployed in long-term investments.
Rezolute Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Rezolute Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Rezolute Inc (RZLT) total assets.
Rezolute Inc Competitors by Total Liabilities
The table below lists competitors of Rezolute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Barnes & Noble Education Inc
NYSE:BNED
|
USA | $445.46 Million |
|
PGIM Short Duration High Yield Opportunities Fund
NYSE:SDHY
|
USA | $134.47 Million |
|
Pes Camanchaca
SN:CAMANCHACA
|
Chile | CL$423.96 Million |
|
Jiangsu Newamstar Packaging Machinery Co Ltd
SHE:300509
|
China | CN¥1.94 Billion |
|
Tianjin Motimo Membrane Tech
SHE:300334
|
China | CN¥360.93 Million |
|
Shenzhen Tongyi Industry Co Ltd
SHE:300538
|
China | CN¥1.27 Billion |
|
Fondul Proprietatea SA
RO:FP
|
Romania | RON216.26 Million |
|
International Money Express Inc
NASDAQ:IMXI
|
USA | $261.42 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Rezolute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Rezolute Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rezolute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rezolute Inc (2012–2025)
The table below shows the annual total liabilities of Rezolute Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.36 Million | +13.88% |
| 2024-06-30 | $11.73 Million | +55.44% |
| 2023-06-30 | $7.55 Million | +155.99% |
| 2022-06-30 | $2.95 Million | -82.14% |
| 2021-06-30 | $16.51 Million | +358.61% |
| 2020-06-30 | $3.60 Million | -65.71% |
| 2019-06-30 | $10.50 Million | +62.45% |
| 2018-06-30 | $6.46 Million | +207.65% |
| 2017-06-30 | $2.10 Million | -1.39% |
| 2016-06-30 | $2.13 Million | -3.57% |
| 2015-06-30 | $2.21 Million | +121.40% |
| 2014-06-30 | $997.92K | -81.05% |
| 2013-06-30 | $5.27 Million | +123.38% |
| 2012-06-30 | $2.36 Million | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more